Grace Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2018 | — | $7.2M | — |
| Dec 2018 | — | — | $6.4M |
| Mar 2019 | — | $11.0M | $16.9M |
| Jun 2019 | — | $3.3M | — |
| Sep 2019 | — | $-759.0K | — |
| Dec 2019 | — | $-4.3M | $16.9M |
| Mar 2020 | — | $13.0M | $14.2M |
| Jun 2020 | — | $11.0M | $12.1M |
| Sep 2020 | — | $8.9M | $11.6M |
| Dec 2020 | — | $25.7M | $26.5M |
| Mar 2021 | — | $55.7M | $50.9M |
| Jun 2021 | — | $53.5M | $41.0M |
| Sep 2021 | — | $114.2M | $36.9M |
| Dec 2021 | — | $111.1M | $33.0M |
| Mar 2022 | — | $108.3M | $30.3M |
| Jun 2022 | — | $104.4M | $38.4M |
| Sep 2022 | — | $100.2M | $34.9M |
| Dec 2022 | — | $96.7M | $26.2M |
| Mar 2023 | — | $68.0M | $27.9M |
| Jun 2023 | — | $64.0M | $21.6M |
| Sep 2023 | — | $66.7M | $27.0M |
| Dec 2023 | — | $64.7M | $18.5M |
| Mar 2024 | — | $61.7M | $23.0M |
| Jun 2024 | — | $59.4M | $19.4M |
| Sep 2024 | — | $56.1M | $15.2M |
| Dec 2024 | — | $52.1M | $11.1M |
| Mar 2025 | — | $66.6M | $22.1M |
| Jun 2025 | — | $63.6M | $20.0M |
| Sep 2025 | — | $62.8M | $16.9M |
| Dec 2025 | — | $64.9M | $18.7M |
| Mar 2026 | — | $63.9M | $17.0M |
| Jun 2026 | — | $48.2M | $13.8M |